Cipla's scion leaves company for 'new horizons'
This article was originally published in Scrip
Executive Summary
Cipla's scion Kamil Hamied, son of vice-chair MK Hamied and nephew of chairman, Dr Yusuf Hamied, is leaving the Indian generic giant.
You may also be interested in...
Will More Indian Family-Owned Firms Hand Over The Baton To PEs?
Private equity firms are among those believed to be in the fray for a stake in India's Cipla, a company with a rich legacy and steeped in history. It’s an ideal case study for buyout funds, according to an investment banker.
Will More Indian Family-Owned Firms Hand Over The Baton To PEs?
Private equity firms are among those believed to be in the fray for a stake in India's Cipla, a company with a rich legacy and steeped in history. It’s an ideal case study for buyout funds, an investment banker tells Scrip.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.